Your session is about to expire
← Back to Search
Researching the Effectiveness of Acceptance-Based Coping During Hospitalization (REACH Trial)
N/A
Waitlist Available
Led By Brandon Gaudiano, Ph.D.
Research Sponsored by Butler Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
To test the effectiveness of Acceptance and Commitment Therapy (ACT) versus enhanced Treatment as Usual (eTAU) delivered by hospital staff for inpatients with psychotic-spectrum disorders.
Eligible Conditions
- Schizophrenia
- Psychosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Acceptance and Commitment Therapy (ACT)Experimental Treatment1 Intervention
ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
Group II: Enhanced Treatment as Usual (eTAU)Active Control1 Intervention
Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acceptance and Commitment Therapy (ACT)
2016
Completed Phase 3
~1470
Find a Location
Who is running the clinical trial?
National Institute of Mental Health (NIMH)NIH
2,931 Previous Clinical Trials
2,744,971 Total Patients Enrolled
254 Trials studying Schizophrenia
89,969 Patients Enrolled for Schizophrenia
Butler HospitalLead Sponsor
131 Previous Clinical Trials
16,446 Total Patients Enrolled
2 Trials studying Schizophrenia
210 Patients Enrolled for Schizophrenia
Brandon Gaudiano, Ph.D.Principal InvestigatorButler Hospital/Brown University